Bambevi (bevacizumab biosimilar) / Apotex - LARVOL DELTA

Cancer News Video Abstract - Dr. Ghassan Abou-Alfa (YouTube) - "IMBRAVE-151, A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer, shared by Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center."

Video

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies (OncLive) - "'It's exciting to see this flurry of activity in cervical cancer. We have tripled the survival [rate], which is heartwarming and incredible for our patients. This field is going to continue to evolve,' Bhavana Pothuri, MD, said. First-Line Metastatic Cervical Cancer Treatment Managing metastatic cervical cancer in the firstline setting includes treating women with de novo stage IVB or recurrent cancer after chemotherapy or radiation, Bradley Monk, MD, FACOG, FACS, said. 'We don't count chemotherapy or radiation as a line of therapy,' he said....'The OS hasn't been accomplished yet,' Thaker said....'In 2 years, I think the algorithm for how we treat patients with recurrent cervical cancer will be completely different. It's the dawn of a new era. It's incredibly exciting,' Huh said."

Media quote

Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada (Canada Newswire) - "Apobiologix...today launched its first oncology therapeutic treatment nationally. The company, a pioneer and leader in oncology biosimilars in Canada, launched Bambevi® (bevacizumab), which is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer."

Biosimilar launch • Brain Cancer • Colorectal Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Canadian Cancer Patients Have New Affordable Treatment Option (Canada Newswire) - “Apobiologix…expanded its leadership in Canada's biosimilar market with the approval of its first therapeutic treatment, Bambevi®. The company, a pioneer and leader in oncology biosimilars in Canada, recently received approval from Health Canada for its first therapeutic product. Bambevi ( bevacizumab) is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer. This approval, coupled with well-established Apobiologix supportive care products, further enables Apobiologix to deliver on its mission to transform access to affordable therapies in oncology and beyond.”

Canadian regulatory • Brain Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Oncology • Ovarian Cancer